Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma

被引：4

作者：

Manson, Guillaume ^{[1
]}

Brice, Pauline ^{[2
]}

Herbaux, Charles ^{[3
]}

Silva, Maria ^{[4
]}

Bouabdallah, Krimo ^{[5
]}

Deau-Fisher, Benedicte ^{[6
]}

Bouteloup, Juliette ^{[7
]}

de Collela, Jean Marc Schiano ^{[8
]}

Nicolas-Virelizier, Emmanuelle ^{[9
]}

Maerevoet, Marie ^{[10
]}

Ghesquieres, Herve ^{[11
]}

Bastard, Aspasia Stamatoulas ^{[12
]}

Antier, Chloe ^{[13
]}

Poizeau, Florence ^{[14
]}

Dercle, Laurent ^{[15
]}

Houot, Roch ^{[16
]}

机构：

[1] Univ Hosp Rennes, Dept Hematol, Rennes, France

[2] Hop St Louis, Dept Hematol, Paris, France

[3] CHRU Lille, Lille, France

[4] Inst Portugues Oncol Lisboa, Dept Hematol, Lisbon, Portugal

[5] Univ Hosp Bordeaux, Dept Hematol, Pessac, France

[6] Cochin Hosp, Dept Hematol, Paris, France

[7] Chalon Ctr Hosp, Dept Hematol, Chalon Sur Saone, Saone & Loire, France

[8] Inst Paoli Calmettes, Marseille, France

[9] Leon Berard Ctr, Dept Hematol, Lyon, France

[10] Hosp Jules Bordet, Brussels, Belgium

[11] Hosp Civils Lyon, Dept Hematol, Ctr Hosp Lyon Sud, Pierre Benite, France

[12] Henri Becquerel Ctr, Rouen, France

[13] Nantes Univ Hosp, Dept Hematol, Nantes, France

[14] Rennes Univ Hosp, Dept Dermatol, Rennes, France

[15] Inst Gustave Roussy, Dept Med Imaging, Villejuif, France

[16] CHU Rennes, Dept Hematol, Rennes, France

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122171

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1549

引用

页数：3

共 50 条

[41] Distribution of anti-PD1/PDL1 autoantibodies in multiple cancer types and potential biomarker role for anti-PD1 therapy
Tan, Q.
Wang, Y.
Liu, S.
Luo, R.
Wang, S.
Liang, T.
Yang, J.
Xing, P.
Yao, J.
Wu, D.
Zhang, Z.
Dai, J.
Yu, X.
Han, X.
Shi, Y.
ANNALS OF ONCOLOGY, 2020, 31 : S1097 - S1098
[42] EFFICACY AND OUTCOME OF ANTI-PD1 THERAPY IN PATIENTS WITH LUNG CANCER BRAIN METASTASIS
Thapa, Bicky
Shah, Bhavan
Lauko, Adam
Ahluwalia, Manmeet
NEURO-ONCOLOGY, 2017, 19 : 39 - 39
[43] Anti-PD1/PDL1 induced psoriasis
Voudouri, D.
Nikolaou, V.
Laschos, K.
Charpidou, A.
Soupos, N.
Triantafyllopoulou, I.
Panoutsopoulou, I.
Tsimpoukis, S.
Aravantinos, G.
Syrigos, K.
Stratigos, A. J.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 53 - 54
[44] Impact of anti-PD1 on TIL phenotype and function
Creasy, Caitlin
Haymaker, Cara
Forget, Marie-Andree
Singh, Gopal
Tapia, Coya
Painter, Jeane Marie
Meric-Bernstam, Funda
Bernatchez, Chantale
Naing, Aung
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[45] Kinase inhibition and anti-PD1 combination therapy
Collingridge, David
LANCET ONCOLOGY, 2020, 21 (07): : 886 - 886
[46] Anti-PD1/PDL1 induced psoriasis
Voudouri, Dimitra
Nikolaou, Vasiliki
Laschos, Konstantinos
Charpidou, Andriani
Soupos, Nikolaos
Triantafyllopoulou, Ioanna
Panoutsopoulou, Ioanna
Aravantinos, Gerasimos
Syrigos, K.
Stratigos, A.
CURRENT PROBLEMS IN CANCER, 2017, 41 (06) : 407 - 412
[47] Bullous pemphigoid under anti-PD1 therapy
Wirbel, C.
Milley, S.
Balme, B.
Dalle, S.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2020, 147 (11): : 795 - 797
[48] How to build anti-PD1 agonist antibodies
Alexandra Flemming
Nature Reviews Immunology, 2023, 23 : 139 - 139
[49] How to build anti-PD1 agonist antibodies
Flemming, Alexandra
NATURE REVIEWS IMMUNOLOGY, 2023, 23 (03) : 139 - 139
[50] Anti-PD1 in the wonder-gut-land
Vetizou, Marie
Trinchieri, Giorgio
CELL RESEARCH, 2018, 28 (03) : 263 - 264

← 1 2 3 4 5 →